The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

10 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.EBI
China Pharmaceutical University
NSD3: Advances in cancer therapeutic potential and inhibitors research.EBI
Peking University
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).EBI
University of Texas Medical Branch (UTMB)
Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.EBI
Shanghai Institute of Materia Medica
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.EBI
Shanghai Jiao Tong University
From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD).EBI
University of S£O Paulo
Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.EBI
Chinese Academy of Sciences
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.EBI
Chinese Academy of Sciences
Fragment-to-Lead Medicinal Chemistry Publications in 2019.EBI
Novartis Institutes For Biomedical Research
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.BDB
Novartis Institutes For Biomedical Research